Hepatitis C virus inhibitors having the general formula
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2006086381A2
公开(公告)日:2006-08-17
[EN] The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as "serine protease") encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease. [FR] La présente invention concerne de manière générale des composés antiviraux et, plus spécifiquement, des composés inhibant la fonction de la protéase NS3 (également désignée sous le nom de "sérine protéase") codée par le virus de l'hépatite C (VHC), des compositions contenant lesdits composés, et des méthodes d'inhibition de la fonction de la protéase NS3.
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009140475A1
公开(公告)日:2009-11-19
Hepatitis C virus inhibitors having general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.